Alzheimer's Disease Trial, Recruiting NCT07127510 Sponsor: Florida Atlantic University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT07127510
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be able to travel to the Florida Atlantic University Clinical Research Unit, speak verbally, and be able to walk.
  • You must be between 65 and 80 years old (inclusive).
  • If you have Alzheimer's disease, you must have a formal diagnosis from your doctor based on clinical assessment AND either a positive amyloid PET scan or a positive FDA-approved test from cerebrospinal fluid or blood.

Who may not be able to join:

  • People younger than 65 or older than 80 years of age.
  • People whose dementia is severe enough that they would need sedation to have an MRI scan.
  • People currently receiving the intravenous anti-amyloid treatments Leqembi or Kinsula.
  • People who have a pacemaker or any other device or implant in their body that is not safe to use with an MRI machine (for example, anything containing metal parts).
  • People who have a history of seizures (epilepsy or similar conditions).
  • People who work night shifts.
  • People who currently have cancer, or who have been diagnosed with cancer in the last 5 years (certain minor skin cancers may be excluded from this rule — confirm with trial site).
  • If you do not have Alzheimer's disease, you may not be eligible if you score below 26 on a standard memory and thinking test called the MoCA.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Corinne Lasmezas, PhD, Florida Atlantic University

Phone: 561-235-4467

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Florida Atlantic University
Registry
ClinicalTrials.gov
Start date
18 March 2026
Est. completion
1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Brain NAD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov